- Volume 14 Issue 5
DOI QR Code
Meta-analysis of Associations of the Ezrin Gene with Human Osteosarcoma Response to Chemotherapy and Prognosis
- Wang, Zhe (Graduate School of Guangxi Medical University) ;
- He, Mao-Lin (Division of Spinal Surgery, The First Affiliated Hospital of Guangxi Medical University) ;
- Zhao, Jin-Min (Department of Orthopedic Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University) ;
- Qing, Hai-Hui (Graduate School of Guangxi Medical University) ;
- Wu, Yang (Graduate School of Guangxi Medical University)
- Published : 2013.05.30
Various studies examining the relationship between Ezrin overexpression and response to chemotherapy and clinical outcome in patients with osteosarcoma have yielded inconclusive results. We accordingly conducted a meta-analysis of 7 studies (n = 318 patients) that evaluated the correlation between Ezrin and histologic response to chemotherapy and clinical prognosis (death). Data were synthesized in receiver operating characteristic curves and with fixed-effects and random-effects likelihood ratios and risk ratios. Quantitative synthesis showed that Ezrin is not a prognostic factor for the response to chemotherapy. The positive likelihood ratio was 0.538 (95% confidence interval [95% CI], 0.296- 0.979; random-effects calculation), and the negative likelihood ratio was 2.151 (95% CI, 0.905- 5.114; random-effects calculations). There was some between-study heterogeneity, but no study showed strong discriminating ability. Conversely, Ezrin positive status tended to be associated with a lower 2-year survival (risk ratio, 2.45; 95% CI, 1.26-4.76; random-effects calculation) with some between-study heterogeneity that disappeared when only studies that employed immunohistochemistry were considered (risk ratio, 2.97; 95% CI, 2.01- 4.40; fixed-effects calculation). To conclude, Ezrin is not associated with the histologic response to chemotherapy in patients with osteosarcoma, whereas Ezrin positivity was associated with a lower 2-year survival rate regarding risk of death at 2 years. Expression change of Ezrin is an independent prognostic factor in patients with osteosarcoma.
- Bal N, Yildirim S, Nursal TZ, Bolat F, Kayaselcuk F (2007). Association of ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type. World J Gastroenterol, 13, 3726-9.
- Boldrini E, Peres SV, Morini S, de Camargo B (2010). Immunoexpression of Ezrin and CD44 in patients with osteosarcoma. J Pediatr Hematol Oncol, 32, e213-7. https://doi.org/10.1097/MPH.0b013e3181e5e247
- Brambilla D, Fais S (2009). The Janus-faced role of ezrin in “linking” cells to either normal or metastatic phenotype. Int J Cancer, 125, 2239-45. https://doi.org/10.1002/ijc.24734
- Bretscher A, Edwards K, Fehon RG (2002). ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol, 3, 586-99. https://doi.org/10.1038/nrm882
- Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M (2005). The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res, 7, R365-73. https://doi.org/10.1186/bcr1006
- Federici C, Brambilla D, Lozupone F, et al (2009). Pleiotropic function of ezrin in human metastatic melanomas. Int J Cancer, 124, 2804-12. https://doi.org/10.1002/ijc.24255
- Foster L, Dall GF, Reid R, Wallace WH, Porter DE (2007). Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. J Bone Joint Surg Br, 89, 1234-8.
- Gautreau A, Poullet P, Louvard D, Arpin M (1999). Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A, 96, 7300-5. https://doi.org/10.1073/pnas.96.13.7300
- Gorlick R (2009). Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res, 152, 467-78. https://doi.org/10.1007/978-1-4419-0284-9_27
- Hong-Jian W, Cheng-Zhang S, Xian-Feng Q, Qiu-Shi H (2007). Expression of ezrin, E-cadherin and focal adhesion kinase in colorectal carcinoma and their clinical significances. World Chin J Digestol, 15, 5.
- Hunter KW (2004). Ezrin, a key component in tumor metastasis. Trends Mol Med, 10, 201-4. https://doi.org/10.1016/j.molmed.2004.03.001
- Khanna C, Wan X, Bose S, et al (2004). The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med, 10, 182-6. https://doi.org/10.1038/nm982
- Kim C, Shin E, Hong S, et al (2009). Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat, 41, 138-44. https://doi.org/10.4143/crt.2009.41.3.138
- Kim MS, Song WS, Cho WH, Lee SY, Jeon DG (2007). Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res, 459, 229-36. https://doi.org/10.1097/BLO.0b013e3180413dbf
- Krishnan K, Bruce B, Hewitt S, et al (2006). Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis, 23, 227-36. https://doi.org/10.1007/s10585-006-9033-y
- Kumar R, Wang RA, Bagheri-Yarmand R (2003). Emerging roles of MTA family members in human cancers. Semin Oncol, 30, 30-7. https://doi.org/10.1053/sonc.2003.37273
- Lau J, Ioannidis JP, Schmid CH (1997). Quantitative synthesis in systematic reviews. Ann Intern Med, 127, 820-6. https://doi.org/10.7326/0003-4819-127-9-199711010-00008
- Li YG, Geng X (2010). A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma. Eur J Cancer Care (Engl), 19, 313-6. https://doi.org/10.1111/j.1365-2354.2008.00970.x
- Martin TA, Harrison G, Mansel RE, Jiang WG (2003). The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol, 46, 165-86. https://doi.org/10.1016/S1040-8428(02)00172-5
- McClatchey AI (2003). Merlin and ERM proteins: unappreciated roles in cancer development? Nat Rev Cancer, 3, 877-83. https://doi.org/10.1038/nrc1213
- Moses LE, Shapiro D, Littenberg B (1993). Combining independent studies of a diagnostic test into a summary ROC curve: dataanalytic approaches and some additional considerations. Stat Med, 12, 1293-316. https://doi.org/10.1002/sim.4780121403
- Ottaviani G, Jaffe N (2009). The etiology of osteosarcoma. Cancer Treat Res, 152, 15-32. https://doi.org/10.1007/978-1-4419-0284-9_2
- Pakos EE,Ioannidis JP (2003). The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer, 98, 581-9. https://doi.org/10.1002/cncr.11546
- Pakos EE, Kyzas PA, Ioannidis JP (2004). Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clin Cancer Res, 10, 6208-14. https://doi.org/10.1158/1078-0432.CCR-04-0246
- Petitti DB (2000). Meta-analysis, decision analysis, and costeffectiveness analysis: methods for quantitative synthesis in medicine. New York, Oxford University Press.
- Qu JT, Wang M, He HL, Tang Y, Ye XJ (2012). The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. J Cancer Res Clin Oncol, 138, 819-25. https://doi.org/10.1007/s00432-012-1149-7
- Salas S, Bartoli C, Deville JL, et al (2007). Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Arch, 451, 999-1007. https://doi.org/10.1007/s00428-007-0474-8
- Shi RL, Li JF, Qu Y, et al (2006). Expression of Ezrin in gastric carcinoma and its significance. Zhonghua Wei Chang Wai Ke Za Zhi, 9, 433-5.
- Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603-5. https://doi.org/10.1007/s10654-010-9491-z
- Sun CX, Robb VA,Gutmann DH (2002). Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci, 115, 3991-4000. https://doi.org/10.1242/jcs.00094
- Vaheri A, Carpen O, Heiska L, et al (1997). The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol, 9, 659-66. https://doi.org/10.1016/S0955-0674(97)80119-6
- Wang HJ, Zhu JS, Zhang Q, Sun Q, Guo H (2009). High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy. World J Gastroenterol, 15, 2016-9. https://doi.org/10.3748/wjg.15.2016
- Wang YF, Shen JN, Xie XB, Wang J, Huang G (2011). Expression change of ezrin as a prognostic factor in primary osteosarcoma. Med Oncol, 28, S636-43. https://doi.org/10.1007/s12032-010-9684-z
- Xu-dong S, Feng LIN, Ping C, et al (2008). Expression of Ezrin protein and its relationship with lung metastasis and survival time of osteosarcoma patients. TUMOR, 28, 4.
- Xu-Dong S, Zan S, Shui-er Z, et al (2009). Expression of Ezrin correlates with lung metastasis in Chinese patients with osteosarcoma. Clin Invest Med, 32, E180-8.
- You-yuan W, Wei-liang C, Zhao-hui Y, et al (2009). Effects of Ezrin gene on the proliferation and invasion activity of human salivary gland adenoid cystic carcinoma. Chin J Stomatol, 44, 5.
- Yu Y, Khan J, Khanna C, et al (2004). Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med, 10, 175-81. https://doi.org/10.1038/nm966
- Quantitative Assessment of the Association of COX-2 (Cyclooxygenase-2) Immunoexpression with Prognosis in Human Osteosarcoma: A Meta-Analysis vol.8, pp.12, 2013, https://doi.org/10.1371/journal.pone.0082907
- MicroRNAs in Body Fluids as Biomarkers for Non-Small Cell Lung Cancer: A Systematic Review vol.13, pp.3, 2014, https://doi.org/10.7785/tcrt.2012.500377
- Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma vol.31, pp.2, 2014, https://doi.org/10.1007/s12032-013-0821-3
- The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults vol.37, pp.9, 2016, https://doi.org/10.1007/s13277-016-5091-1
- Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer vol.50, pp.4, 2017, https://doi.org/10.1590/1414-431x20165356